Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. won local approval of the first China-made trophoblast cell-surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC), sacituzumab tirumotecan, as a third-line therapy for advanced breast cancer.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Advanz, Anavex, Aop Orphan, Beigene, Cevomed, Exelixis, Gsk, Kelun-Biotech, Lin, Novartis, Oncopeptides, Satsuma, Tuhura, Valneva.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acadia, Adcendo, Agenus, Alector, Duality Biologics, Empyrean, Eos, Idorsia, Kronos, PTC, Saniona.
Researchers at the University of Rochester have described a neuroimaging-based biomarker that could identify individuals with early psychosis, and improved their identification when it was added to a standard neurocognitive diagnostic test. In a group of roughly 160 participants in the Human Connectome Early Psychosis Project, individuals who were in the early stages of psychosis had stronger connections from the thalamus (a midbrain sensory processing area) to the cortex, but weaker connections between different cortical areas, than controls.
RSS
